Clinical characteristics and risk factors associated with Pneumocystis jirovecii infection in patients with solid tumors: study of thirteen-year medical records of a large cancer center

• Published in: BMC cancer 2021-09, Vol.21 (1), p.1-9, Article 987
• Main Authors: Takeda, Koichi, Harada, Sohei, Hayama, Brian, Hoashi, Kosuke, Enokida, Taisuke, Sasaki, Toshiharu, Okamoto, Koh, Nakano, Kenji, Ohkushi, Daisuke
• Format: Article
• Language: English
• Subjects: Beta-D-glucans; Breast cancer; Cancer therapies; Cell number; Chemotherapy; Chest; Complications and side effects; Corticosteroids; Diagnosis; Disease prevention; Dosage; Drug dosages; Hematology; Hospitals; Immunosuppressive agents; Invasive fungal infections; Lung cancer; Lung diseases; Lung diseases, Fungal; Lymphocytes; Lymphopenia; Malignancy; Medical records; Mortality; Mycoses; Patients; Plasma; Pneumocystis jirovecii; Pneumonia; Prednisone; Radiation therapy; Risk factors; Solid tumors; Steroids; Tuberculosis; Tumors
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-021-08727-2

Background Pneumocystis jirovecii pneumonia (PCP)-related risk factors among patients with solid tumors are not completely defined. Thus, we aimed to characterize PCP cases with underlying solid tumors, to highlight the factors contributing to its development besides the prolonged use of moderate-to-high dose corticosteroids. Methods We retrospectively reviewed the medical records of patients with solid tumors diagnosed with PCP between 2006 and 2018 at a cancer center in Tokyo, Japan. Demographic and clinical data were collected, which included malignancy types, total lymphocyte count, coexisting pulmonary disease, chemotherapy, radiation therapy, corticosteroid use, and PCP-attributable mortality. Results Twenty cases of PCP with solid tumors were documented in 151,718 patients and 788,914 patient-years. Lung cancer (n = 6, 30%) was the most common underlying tumor, followed by breast cancer (n = 3, 15%). Only six (30%) patients were taking a dosage of [greater than or equai to]20 mg prednisone equivalents daily for [greater than or equai to]4 weeks from the onset of PCP. Among the remaining 14 patients, seven (50%) had coexisting pulmonary diseases, 10 (71%) had received chemotherapy within 90 days prior to PCP diagnosis, seven (50%) had undergone chest radiation therapy before PCP diagnosis, seven (50%) had received only intermittent corticosteroids, and one (7%) received no corticosteroids. Mortality attributable to PCP was 40%. Conclusions More than half of the patients were not taking a dosage of [greater than or equai to]20 mg prednisone equivalents daily for [greater than or equai to]4 weeks. Multiple other factors (e.g., lymphocytopenia, radiation to chest) may have potentially contributed to PCP in patients with solid tumors in a composite manner. We need to establish a method for estimating the likelihood of PCP taking multiple factors into account in this patient population. Keywords: Beta-D-glucans, Corticosteroids, Invasive fungal infections, Mycoses, Solid tumors, Pneumocystis jirovecii